NCT06436274View on ClinicalTrials.gov

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.

PHASE4RecruitingINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2027

Conditions
Human Papilloma VirusHiv
Interventions
BIOLOGICAL

GARDASIL®9

GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

BIOLOGICAL

Menveo®/Menactra®

Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

Trial Locations (3)

2001

RECRUITING

Wits RHI, University of the Witwatersrand, Johannesburg

0000

RECRUITING

Botswana Harvard Health Partnership, Gaborone

+250

RECRUITING

Ministry of Health and Center for Family Health Research, Kigali

All Listed Sponsors
collaborator

University of Witwatersrand, South Africa

OTHER

collaborator

Botswana Harvard Health Partnership

UNKNOWN

collaborator

Ministry of Health, Rwanda

OTHER_GOV

collaborator

Fred Hutchinson Cancer Center

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Karolinska Institutet

OTHER

lead

Massachusetts General Hospital

OTHER

NCT06436274 - Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. | Biotech Hunter | Biotech Hunter